In
malignant gliomas, the management of symptoms and minimization of side effects assume major importance.
Corticosteroids provide transient relief from neurological symptoms. However, treatment with
steroids is also commonly associated with considerable side-effects including:
hyperglycemia,
osteoporosis,
myopathy,
lymphopenia and others. Sometimes,
antiepileptic drugs may contribute to clinical decline of neuro-oncological patients in stable disease not only by neuropsychological impairment but also by metabolic interations. Several studies have demonstrated a high frequency of
hyponatremia among patients treated with
carbamazepine and particularly with oxacarbamazepine.
Venous thromboembolism is a common complication in patients with
cancer and it is particularly high in
malignant gliomas, occurring in approximately 20-30% of such patients. Prophylactic treatment in patients with
glioblastoma is a key topic. The role of prophylaxis has not yet been established with certainty. Overall the data show a clear reduction of venous thromboembolic events in patients treated with intermittent pneumatic compression (IPC). The addition of
enoxaparin dose of 6.000 UI, starting in the
perioperative period, induces an increase of major
bleeding events. In the absence of availability of IPC, the use of
enoxaparin 4.000 UI in addition to graduated
compression stockings, reduces thromboembolic events without major
bleeding events.